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SUMMARY
Phosphorylation of endogenous inhibitor proteins specific for type-1 Ser/Thr
phosphatase (PP1) provides a mechanism for reciprocal coordination of kinase and
phosphatase activities. Phosphorylation of Thr38 in the inhibitor protein CPI-17
transduces G-protein-mediated signaling into a > 1000-fold increase of inhibitory
potency toward myosin phosphatase. We show here the solution NMR structure of
phospho-T38-CPI-17 with r. m. s. d. of 0.36 ± 0.06 Å for the backbone secondary
structure, which reveals how phosphorylation triggers a conformational change and
exposes the PP1 inhibitory surface.

This active conformation is stabilized by the

formation of a hydrophobic core of intercalated side-chains, which is not formed in a
phospho-mimetic D38 mutant form of CPI-17. Thus, the profound increase in potency
of CPI-17 arises from phosphorylation, conformational change and hydrophobic
stabilization of a rigid structure that poses the phosphorylated residue on the protein
surface and restricts its hydrolysis by myosin phosphatase. Our results provide
structural insights into transduction of kinase signals by PP1 inhibitor proteins.
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INTRODUCTION
Type-1 Ser/Thr phosphatase (PP1) is conserved among all eukaryotes and is
responsible for regulation of a plethora of cellular functions,.

A specific multisubunit form

of PP1, called myosin phosphatase, is a ubiquitous enzyme that functions in various
signaling circuits (Hartshorne, et al, 2004). Myosin phosphatase is a trimeric holoenzyme
consisting of a catalytic subunit of PP1 and a myosin targeting MYPT1 subunit with an
accessory M21 subunit (Hartshorne, et al, 2004). The N-terminal ankyrin-repeat domain of
MYPT1, including a PP1 binding site, functions as an allosteric regulator of the catalytic
subunit.

On the other hand, C-terminal domain is phosphorylated by multiple kinases,

ROCK, ZIPK and ILK, that is involved in the inhibition of myosin phosphatase in response
to G-protein activation (Trinkle-Mulcahy, et al, 1995). In smooth muscle, agonist-induced
activation of G-protein enhances the activity of Ca2+/calmodulin-dependent myosin
light-chain kinase, and coincidently suppresses the activity of myosin phosphatase via the
activation of kinases ROCK and PKC (Kitazawa, et al, 1991; Somlyo, et al, 2003).

The

inhibition of myosin phosphatase is required for robust and sustained myosin
phosphorylation in response to agonist stimuli (Dimopoulos, et al, 2007). The inhibition of
myosin phosphatase is also involved in regulation of cytoskeletal reorganization during cell
migration (Kawano, et al, 1999) and cytokinesis (Matsumura, 2005).
In addition to direct phosphorylation of the MYPT1 subunit myosin phosphatase is
regulated by a specific inhibitor protein, CPI-17, that is predominantly expressed in smooth
muscles and neurons (Eto, et al, 1997; Eto, et al, 2002; Woodsome, et al, 2001).
Phosphorylation of CPI-17 at Thr38 is necessary and sufficient to convert the protein into a
potent inhibitor of myosin phosphatase (Eto, et al, 1995; Kitazawa, et al, 2000; Koyama, et al,
2000; Pang, et al, 2005).

Other PP1 holoenzymes in cells are insensitive to

phospho-CPI-17 (P-CPI-17) (Senba, et al, 1999).

One example is a glycogen-bound form

of PP1 holoenzyme, which binds P-T38-CPI-17 but dephosphorylates it .

In contrast, with
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myosin phosphatase there is binding of P-T38-CPI-17, but the hydrolysis step is arrested,
resulting in formation of inactive complex.

Thus, P-T38-CPI-17 can be a substrate or an

inhibitor of different forms of PP1, depending on regulatory subunits (Eto, et al, 2004). In
smooth muscle cells, rapid phosphorylation of CPI-17 at Thr38 occurs in parallel to
phosphorylation of myosin via activation of Ca2+-dependent PKC, followed by prolonged
phosphorylation, maintained via RhoA/ROCK signal (Dimopoulos, et al, 2007).
Phosphorylation of CPI-17 is reduced through a cGMP-dependent pathway in response to
nitric oxide release, in parallel to muscle relaxation (Bonnevier, et al, 2004; Etter, et al, 2001).
Thus, in smooth muscles phosphorylation of CPI-17 functions to inhibit myosin phosphatase
and thereby promote myosin phosphorylation and contraction.

Fluctuation in the expression and the phosphorylation levels of CPI-17 is associated
with smooth muscle-related diseases, such as intestinal bowel disease (Ohama, et al, 2003),
asthma (Sakai, et al, 2005), pulmonary hypertension (Dakshinamurti, et al, 2005), and
diabetic dysfunction of smooth muscle (Chang, et al, 2006; Xie, et al, 2006). In Purkinje
neurons, CPI-17 is essential to maintain G-protein-mediated AMPA receptor internalization
and generate long-term synaptic depression in response to stimulation(Eto, et al, 2002). In
addition, the upregulation of CPI-17 was found in tumor cells, which causes
hyperphosphorylation of tumor suppressor merlin (NF2) and transformation of cells (Jin, et
al, 2006). Therefore, CPI-17 poses a potential target of pharmaceutical approaches for these
diseases.
Determination of the three-dimensional (3D) structure of unphospho-CPI-17 by
NMR revealed a 2x2 pairing of a four-helix bundle, forming a unique V-shape structure
(Ohki, et al, 2001).

The phosphorylation site, Thr38, is located in a loop structure (P-loop)

at the N-terminus, sitting in a cavity between helices (Ohki, et al, 2001). When Thr38 is
substituted for Asp to mimic phosphorylation, the P-loop becomes exposed to solvent,
4

suggesting a conformational change of the P-loop upon activation of CPI-17 (Ohki, et al,
2003).

However, structural analysis of the basis for enhanced inhibition of myosin

phosphatase by CPI-17 was limited because the D38-form of CPI-17 is significantly less
potent, compared with phospho (P)-T38-CPI-17 (Ohki, et al, 2003). We concluded that
despite a conformational change in the D38 protein, this structure was not the same as that of
the highly potent and fully activated P-T38-CPI-17.

Therefore we prepared CPI-17 protein

fully phosphorylated with PKC and determined the 3D structure using multidimensional
NMR techniques.

The 3D structure indicates a global conformational switch upon

phosphorylation of CPI-17 at Thr38, shows differences relative to the phospho-mimetic D38
structure and exposes novel interactions between P-CPI-17 and myosin phosphatase.
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RESULTS
Phosphorylation of CPI-17(22-120)
The inhibitory domain of CPI-17 comprised of residues 22-120 is conserved among
the CPI-17 family of PP1 inhibitor proteins, such as PHI-1, KEPI and GBPI (Figure 1A).
The recombinant 13C/15N-labeled 22-120 protein was phosphorylated to completion by
extended incubation with purified PKC (Supplementary Figure S1), and subjected to a series
of multidimensional NMR experiments (Supplementary Figure S2, and S3). Figure 1B shows
part of the 1H-15N HSQC spectrum of 13C/15N-labeled P-CPI-17 (red) superimposed on the
previous spectra of unphosphorylated (gray) and Asp-substituted D38-CPI-17 (blue)
(22-120) proteins (Ohki, et al, 2003). The backbone amide resonance of Thr38 is shifted to
downfield upon phosphorylation (Figure 1B).

This phosphorylation-dependent downfield

shift is consistent with a previous report on phosphorylation of the tau protein (Landrieu, et
al, 2006) .

In addition, the phosphorylation at Thr38 induces a relatively large chemical

shift change of amide resonances from the neighbor residues in the phosphorylation loop
(P-loop), such as V39 and Y41.

The chemical shifts of these residues in P-T38-CPI-17 did

not match those in the D38-form of CPI-17 (blue).

This suggests that the conformation of

the phosphorylated protein differs from the conformation of the protein with a
“phosphomimetic” mutation to introduce an Asp at the same residue. Overall the profiles of
HSQC spectra in the full-scale chart (Supplementary Figure S2) are similar in all three forms
of CPI-17 examined by NMR. Furthermore, there was no evidence of multiple conformation
states in the spectrum of P-T38-CPI-17.

Structure of phospho-T38-CPI-17
The 3D structure of P- T38-CPI-17 was calculated using 1,518 structural restraints
obtained from the NMR data (Supplementary Figure S3), summarized in Supplementary
Table S1. Overall the topology of P-T38-CPI-17 is composed of a long loop with the
6

phosphorylation site, Thr38, followed by a left-handed 4-helix bundle (termed A to D from
the N-terminus) (Figure 2). The four helices are arranged in an anti-parallel orientation. The
structure of residues 22 to 31 at the N terminus of the truncated protein was in a flexible
conformation, seen by lack of long-range NOE. This conclusion is supported by very small
heteronuclear 15N-{1H} NOE values (Supplementary Figure S4) and the fast H-D exchange
rates (data not shown) of these10 residues.

In contrast, the conserved region of residues 32

to 40 with phospho-Thr38 (P-Thr38), termed the P-loop, converged into a single
conformation with a backbone r.m.s.d. of 1.18 + 0.27 Å, with relatively higher heteronuclear
15

N-{1H} NOE values (Supplementary Figure S4, red). The P-Thr38 side chain is exposed to

solvent, and the P-loop lays on the surface of the four-helix bundle. The side chains of Val37
and Val39 face into the protein, making contacts with Ile56 and Tyr41/Val52/Ile77,
respectively. These two Val residues function to anchor the P-loop to the four-helix bundle by
hydrophobic interactions of the aliphatic side chains.

Comparison between unphospho-, phospho-, and Asp-substituted CPI-17 structures
Comparison of P-T38-CPI-17 structure with that in the unphospho-form (U-CPI-17)
and D38-form (Ohki, et al, 2003) reveals global conformational change in response to
phosphorylation (Figure 3) (Table S2). The most remarkable difference is the position of the
key residue, Thr38, whose side chain comes out of a cavity between A and B helices upon
phosphorylation. When structures are superimposed using the A/D helix pair for alignment
(Figure 3, bottom), the phosphorylation at Thr38 is seen to trigger a swinging motion of the
P-loop around the A-helix, resulting in 8.1 Å movement of residue 38. The swing of the
P-loop is coupled with a right-handed rotation of A-helix by 29 degrees, along with a
complementary rotation of the D-helix. These rotations expose new surfaces of both helices
that become available for binding to myosin phosphatase.

Similar to U-CPI-17, the A/D

helix-pair in P-T38-CPI-17 is stabilized by hydrophobic residues as shown in Figure 3. In
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concert with motion of the A-helix, the B/C helix-pair becomes close to the A/D helix-pair.
This aligns the four helices into an anti-parallel bundle (Table S3).

The average distance

between the four helices becomes 15 % shorter (Table S3), and the compaction of the
structure causes the overall surface area of the protein to be reduced from 7,221 to 6,374 Å2.
Substitution of T38 to Asp results in the P-loop becoming exposed to solvent, consistent with
changes in P-form.

However, the re-alignment of four helices is not evident in the D38

protein relative to the U-CPI-17, and the overall structure remains V-shape (Figure 3, center).

Formation of hydrophobic core
The phosphorylation-induced compression of the four helices gathers Tyr41 in the
P-loop, Leu46/Val52 in A-helix, and Ile77/Leu80/Leu81 in B-helix into a stable hydrophobic
core (Figure 4A). For example, the distance between Val 52 and Ile77 Cα atoms shortens
from 19.0 to 6.4 Å. Such hydrophobic clustering likely functions to stabilize the
anti-parallel-aligned four-helix bundle of P-CPI-17. This stabilization reflects in higher
heteronuclear NOE value of P-T38-CPI-17, compared with U- and D38-CPI-17
(Supplementary Figure S3).

We assayed thermal stabilities of U-and P-T38-CPI-17, and

indeed, phosphorylation increased the mean melting temperature Tm from 59 °C (U-CPI-17)
to 64 °C (P-T38-CPI-17), showing an effect on the thermodynamic stability of the protein.
We attribute this change to the hydrophobic core in P-T38-CPI-17 (Figure 4B).

The

hydrophobic core is not well-defined in the D38-CPI-17 structure (Figure 4A, middle).
Consistent with this observation, we found the thermal stability of D38-CPI-17 was lower
(Tm = 54 °C), compared to P-T38-CPI-17 (Figure 4B).

Overall, the structure and thermal

stability are consistent with the idea that phosphorylation but not mutation to an acidic
residue triggers condensation of the protein into a rigid structure, with a surface topography
distinctly different from the unphosphorylated protein.
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The hydrophobic core of P-T38-CPI-17
We examined effects of mutation of residues in the hydrophobic core on the
inhibition of purified myosin phosphatase, using wild type CPI-17 and Y41A, W55A,
D73A/E74A, and I77A/L80A/L81A mutants. All these recombinant CPI-17, were equally
phosphorylated by purified PKC, suggesting that the mutations do not impair reaction with
Thr38 (Table S4). However, the phosphorylated mutant CPI-17 showed different inhibitory
potency (Figure 5A). Mutation at either Trp55 or Asp73/Glu74 caused moderate reduction in
inhibitory potency, and the triple mutation of Ile77/Leu80/Leu81 showed greatly reduced
potency, to an IC50 of around 100 nM. Our previous data showed that an Ala-mutation at
Tyr41 (Y41A) eliminated the inhibitory activity of CPI-17 (Hayashi, et al, 2001). Thermal
stability of the Y41A protein (Tm = 56 °C) was lower than that of wild type (Figure 4B,
cross). We concluded that the hydrophobic clustering of Y41 and Ile77/Leu80/Leu81 was
required for CPI-17 to act as an inhibitor for myosin phosphatase. The function of CPI-17
mutated in the hydrophobic core was examined using beta-escin-permeabilized vas deferens
smooth muscle tissues (Figure 5B).

Because CPI-17 is present at only negligible levels in

vas deferens smooth muscle, phorbol ester (PDBu, a PKC activator) stimulation does not
induce force production at limiting Ca2+ concentrations (Figure 5B, arrowhead) (Woodsome,
et al, 2001).

Doping of recombinant U-CPI-17 into a permeabilized vas deferens smooth

muscle strip restored PDBu-induced force production at clamped Ca2+ concentration,
suggesting that PKC induced the phosphorylation of CPI-17 causing inhibition of the
endogenous myosin phosphatase in the strip (Figure 5B, double arrowhead). The
triple-mutant CPI-17, I77A/L80A/L81A or Y41A (Figure 5B), did not induce PKC-mediated
smooth muscle contraction, suggesting that the formation of hydrophobic core is necessary
for CPI-17 to inhibit myosin phosphatase in tissues. On the other hand, CPI-17 mutants
D73A/E74A and W55A supported PDBu-induced force production. The maximum extent
and the rate of force development were slightly lower with these mutant proteins, compared
9

with wild type -17. We note that D73, E74 and W55 are conserved among CPI-17 from
various species, so changes in these residues have not survived probably because of the
changes in properties. .

Modeling of the interaction between P-T38-CPI-17 and myosin phosphatase
The phospho-pivot computer modeling method was used to examine hypothetical
docking of P-T38-CPI-17 with myosin phosphatase (Eto, et al, 2004; Matsuzawa, et al,
2005a; Matsuzawa, et al, 2005b).

The phosphate group of P-T38-CPI-17 was set into the

active site of PP1δ•MYPT1(1-299) complex (Terrak, et al, 2004), and 186,624 in-silico
complexes were generated by rotating P-T38-CPI-17 around the phosphorus atom as a pivot.
Each model complex was scored based on only atomic distances between two proteins.

The

modeling yields one converged structure of P-CPI-17 on myosin phosphatase (Figure 6A). In
this complex, the P-loop fits in the active site groove of PP1, from the cavity of
ankyrin-repeat domain toward the N-terminal alpha-helical segment of MYPT1 (Terrak, et al,
2004). This model suggests that four Arg side chains in P-loop, Arg 33, 36, 43, and 44, are
involved in the interaction with myosin phosphatase, in addition to phospho-Thr38. This is
consistent to our previous results that an Ala mutation of CPI-17 at Arg 43 and Arg 44
impairs the inhibitory potency over 40 fold (Hayashi, et al, 2001).

Interestingly, this model

positions Asp5 on N-terminal segment of MYPT1 in close proximity to Arg44 of
P-T38-CPI-17 (Figure 6A).

Experimental testing of this model using immobilized peptides

corresponding to MYPT1 segments (1-19) and (24-41) showed weak binding of
P-T38-CPI-17 to MYPT1(1-19), but not to MYPT1(24-41) (Figure 6B). Thus, the N-terminal
segment of MYPT1 (1-19) is possibly involved in the interaction with P-CPI-17.
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DISCUSSION
From comparison of the structures of the inactive U-CPI-17 and the active
P-T38-CPI-17 we identify a conformational transition upon phosphorylation of CPI-17 at
Thr38.

The phosphorylation induces a swing of the P-loop and a formation of the

hydrophobic core to lock and stabilize a condensed active conformation of P-T38-CPI-17.
We conclude that this swing-and-lock mechanism of CPI-17 is responsible for potent and
specific inhibition of myosin phosphatase to switch phosphorylation levels of myosin and
merlin in response to G-protein activation. All PP1 specific inhibitor proteins are regulated
by phosphorylation, and five of them are in the CPI-17 family, based on the similarity of the
sequences including residues in the hydrophobic core identified here by NMR , so these
results should apply to other CPI-17 family members. On the other hand, phosphorylation of
another class of PP1 inhibitors, inhibitor-1 and DARPP-32, apparently only induces a minor
conformational change in the molecule, despite over 1000-fold increase in the inhibitory
potency (Endo, et al, 1996; Neyroz, et al, 1993).

The phosphorylation-induced

conformational switch seems to be a unique feature in the CPI-17 family of proteins.

Asp- or Glu-substitution of Ser or Thr is often used for mimicking phosphorylation
of proteins.

One example is the activation loop of protein kinases. Phosphorylation of

protein kinases in the activation loop is required for full activity, and it can be mimicked by
substitution with Asp or Glu (Zhang, et al, 1995).

The phosphate group in the activation

loop of kinases directly forms salt bridges with Arg residues in N-terminal domain
(Canagarajah, et al, 1997; Johnson, et al, 1996) and the effectiveness of Glu or Asp suggests
these residues can form salt bridges with the same Arg. In contrast the phosphate of
P-T38-CPI-17 is exposed to solvent and interacts instead with the active site of PP1 in
myosin phosphatase.. Asp-substitution at Thr38 induces a swing of the P-loop, but not the
same re-alignment of helices or formation of the hydrophobic core in the protein as is formed
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when T38 is phosphorylated (Ohki, et al, 2003).

The failure of hydrophobic clustering in

D38-CPI-17 is evidenced by lower thermal stability. Without the hydrophobic core there is a
100-fold lower inhibitory potency of D38-CPI-17 compared to P-T38-CPI-17.

Thus, the

negative charge of a carboxyl group is insufficient for completion of the conformational
switching in CPI-17. This gives an example of where an acidic side chain is not
phosphomimetic, offering a note of caution to the common practice of using properties of
mutated proteins to make conclusions about effects of phosphorylation.

Currently, about 150 protein structures with phospho-Thr are listed in PDB database.
In most cases, the phosphate group is directly tethered to other residues in the same protein
via salt bridges and/or hydrogen bonds. In this way the phosphate drives formation of a new
protein conformation that is stabilized by these intramolecular interactions, as seen in
glycogen phosphorylase-a and protein kinases (Johnson, et al, 1996; Sprang, et al, 1988).
Another example is the NMR structure of a 44-residue P-Thr peptide mimicking the
forkhead-associated (FHA) domain of human Ki67 protein in the complex with its receptor,
the human nucleolar protein hNIHK, where the phosphate functions as a ligand (Byeon, et al,
2005). Our studies reveal a different mechanism of phosphorylation-induced conformational
change. The phospho conformation of the CPI-17 P-loop is stabilized without a hydrogen
bond or salt bridge to the phosphate group from other residues in the protein.

Based on

heteronuclear NOE data, the P-loop of unphosphorylated CPI-17 is highly flexible and this
presumably exposes Thr38 to kinases, such as PKC and ROCK. Upon the phosphorylation of
T38 the side chains of neighboring V37, V39 and Y41 anchor the P-loop to the hydrophobic
core formed between the helices that restrains the overall solution structure.

The rigid

structure of phosphorylated P-loop is likely critical for the potent inhibition of the
phosphatase by positioning the phosphate relative to other residues in CPI-17 that form
contacts with MYPT1 and PP1. When the hydrophobic core of P-T38-CPI-17 is perturbed by
12

Ala-substitution of Tyr41, the P-Thr38 residue is readily dephosphorylated by myosin
phosphatase (Hayashi, et al, 2001). We propose that the rigidity of the structure due to the
hydrophobic core is key to preventing hydrolysis of the P-T38, making P-T38-CPI-17 an
inhibitor instead of a substrate. Thus, the swing-and-lock mechanism of CPI-17 activation
restricts flexibility of the P-loop and protects P-Thr38 from being hydrolyzed at the active
site of myosin phosphatase. Interestingly, P-T38 is hydrolyzed by other PP1 holoenzymes,
such as glycogen phosphatase (a heterodimer of PP1 plus GM subunit), so phospho-CPI-17
is both a substrate and an inhibitor, depending on the form of PP1 it encounters.
Previously, phospho-pivot modeling with D38-CPI-17 (PDB: 1J2N) and monomeric
PP1 alpha isoform catalytic subunit (1IT6) predicted critical roles for residues at the active
site of PP1δ, namely D137, D193, R220, Y271, and E274

Indeed, these residues are

necessary for the binding of PP1 δ with P-T38-CPI-17 in an in vitro assay (Matsuzawa, et al,
2005a).These same residues at the PP1 active site seem to be involved in the model of the
P-T38-CPI-17•PP1δ•MYPT1(1-299) complex.

However, the best fitting model was

obtained when the pivot phosphorus atom was set at a position 0.5 Å away from the active
site. Thus, the phosphate group is not in an optimum position for hydrolysis in this model.
We speculate that weak interactions of the MYPT1 subunit with P-T38-CPI-17, perhaps
involving the MYPT1 N-terminal (1-19) segment, displaces phospho-Thr38 from being in an
optimum position at the PP1 active site for dephosphorylation. Some involvement of MYPT1
seems to be needed to account for the inhibitor vs. substrate reaction of P-T38-CPI-17 with
different PP1 holoenzymes.

It is noteworthy that the phospho-pivot model positions the unstructured N-terminal
tail of CPI-17 near the MYPT1 ankyrn repeat domain. Other CPI-17 family members, PHI-1
and KEPI, also inhibit myosin phosphatase, but with different potencies. The IC50 for PHI-1
(50 nM) is 50-fold higher than that for CPI-17, whereas KEPI inhibits myosin phosphatase
13

with IC50 of 0.1 nM (Erdodi, et al, 2003; Eto, et al, 1999). It is possible that the N-terminal
tail of the different CPI-17 family members functions as a sensor for different regulatory
subunits of PP1,

This gives us a future direction for studying functional diversity in the

CPI-17 family. Despite a focus on the MYPT1 N terminal domain we cannot completely rule
out involvement of the MYPT1 C-terminal domain and/or the M21 subunit in specific
recognition of P-CPI-17.

Other PP1 inhibitor proteins are known to contact both PP1

catalytic and regulatory subunits to form trimeric complexes that account for their selective
inhibition of PP1 in different contexts. One example is inhibitor-1 binding to GADD-34 that
is bound to PP1, and other examples are inhibitor-2 binding to either neurabin or KPI-2 that
both bind PP1 at independent sites. (Connor, et al, 2001; Terry-Lorenzo, et al, 2002; Wang, et
al, 2002). Inhibitor-2 also binds to PP1 that is engaged with an VxF motif in Nek2A, forming
a heterotrimer with PP1 as the bridging protein (Eto, 2002 and Li 2007) Direct contact
between regulatory subunits and PP1 inhibitor proteins is an attractive idea to provide
signaling specificity for controlling individual PP1 complexes. The structure of an activated
PP1 inhibitor gives general insight into phosphorylation-dependent conformational changes
and regulation of cellular PP1, and opens a door to understanding mechanisms of signaling
crosstalk between kinases and phosphatases.
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METHODS
Proteins: The cDNA of CPI-17 was cloned from pig aorta smooth muscle library.
Recombinant CPI-17 (22-120) for NMR was prepared using pET30 bacterial expression
vector with the minimal medium containing 15N-ammnonium chloride and/or 13C-glucose as
the sole source of nitrogen and/or carbon. This method yields the uniformly stable-isotope
labeled (> 95 %) sample for NMR spectroscopy (Ohki, et al, 2001; Ohki, et al, 2003). CPI-17
proteins for other assays are expressed as full-length versions with N-terminal His6- and
S-tag™ sequences (Eto, et al, 2003). Phosphorylation of the protein was performed with an
active fragment of PKC.

The active fragment of PKC was extracted from human red cells

with hypotonic buffer and purified by ammonium sulfate precipitation, and sequencial
column chromatographies using DEAE-Sepharose, Phenyl-Sepharose, Q-Sepharose and
Protamine-agarose. Stoichiometric phosphorylation of CPI-17 was verified by urea-PAGE
analysis (Figure S1), as described previously (Eto, et al, 2003).

Anti-P-T38-CPI-17 IgY

was prepared using synthetic phospho-peptide as an antigen and purified by affinity
chromatography, as described previously (Kitazawa, et al. 2000) (Aves Lab, Tigard OR).
NMR structure determination: All NMR data for ~1 mM P-T38-CPI-17 (in 50 mM
phosphate buffer pH 6.8, 100 mM KCl, 1 mM DTT, and 0.02 % NaN3) were recorded on a
Varian INOVA750 spectrometer. The sample temperature was kept at 25.0 oC. A set of twoand three-dimensional NMR data was obtained for resonance assignments (Bax, et al, 1992).
Homonuclear 2D-NOESY, 15N-edited NOESY, and 13C-edited NOESY with mixing time of
100 msec were recorded to collect distance information. To obtain the information about
hydrogen bonding, amide proton H-D exchange was monitored by 1H-15N HSQC.
2D-HMQC-J spectra were also recorded to obtain dihedral angle constraints. All NMR data
were processed using nmrPipe/nmrDraw (Delaglio, et al, 1995) and were analyzed with PIPP
(Garrett, 1991).

Structure calculation was carried out using X-PLOR version 3.851
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(Brunger, et al, 1998; Kleywegt, et al, 1998). Quality of each coordinate was examined by
using AQUA/procheck-NMR (Laskowski, et al, 1996).

The Ramachandran plot analysis of

the final structures showed that 1.7 ± 1.1% of non-glycine and non-proline residues were in
the disallowed regions.

Structural analysis: All structural images were drawn with MOLMOL (Koradi, et al, 1996),
Molscript (Kraulis, 1991), and Raster3D (Merrit, et al, 1997). Vector geometry mapping and
calculations of surface potential and area were done using an algorithm of Yap, et al. (Yap, et
al, 2002) and PyMol Molecular Graphic System (http://www.pymol.org), respectively.

The

rotation angle of A-helix was estimated from mean value of differences on Calpha-Cbeta
angle of each residue.

Phospho-pivot modeling: An in silico model of the ternary complex, P-T38-CPI-17 / PP1
delta / MYPT1(1-299) was obtained using the phospho-pivot modeling method, as described
previously (Matsuzawa, et al, 2005a; Matsuzawa, et al, 2005b). Structural data of
P-T38-CPI-17 (present study) and the myosin phosphatase complex of MYPT1(1-299) and
PP1 delta (Terrak, et al, 2004) were used for the modeling. The best result was obtained
when the phosphate group of P-CPI-17 was placed at a point 0.5 Å-away from the putative
phosphorus position.

The atomic distance violation was set with the threshold of 3.5 Å

(Ca-Ca), or 2.0 Å (N-O, N-N, O-O). Models without distance violation between main chain
atoms, identified as 68 out of 186,624 models, were subjected to an energy minimization
process with permitted of structural adjustments on both molecules, using AMBER force
field on SYBYL/BIOPOLYMER (Tripos Inc.).
CPI-17 were used for the energy calculation.
shown in Table S5.

In this modeling atoms within 8 Å of
The results of energy minimization were

The orientation of P-CPI-17 against MYPT1•PP1 complex is the same

in 4 of the best 5 models. Both electrostatic and hydrogen-bonding energy values dominantly
16

contribute to the total binding force.

The best model (shown in Figure 6A) includes 15

atomic violations.

Assays: CD spectrum measurements were performed on a JASCO 720 spectropolarimeter at
various temperatures (20 – 95 °C) with 20 µM U- and H6S-P-T38-CPI-17 full-length proteins
in phosphate-buffered saline. Thermal stability of CPI-17 was assessed via the melting
temperature (Tm ) from the plot of molar ellipticity at 222 nm against the temperature.
Other assays were carried out at 20 °C.
not shown).

The H6S-tag does not affect the CD spectrum (data

The inhibitory potency of CPI-17 proteins was measured using myosin

phosphatase purified from pig aorta smooth muscle with 0.5 µM 32P-labeled phospho-myosin
light chain as a substrate, at 20 °C (Eto, et al, 2003).

The Ca2+ sensitizing effect of CPI-17

protein was examined at 20 °C in vas deferens smooth muscle strips permeabilized with
beta-escin (Masuo, et al, 1994).

This tissue preparation s depleted to a minimum amount of

endogenous CPI-17, but retains other regulatory proteins, such as myosin phosphatase, PKC
and ROCK (Woodsome, et al, 2001).

Binding assay of P-CPI-17 was performed with

synthetic segments of MYPT1 (1-19) and (24-41) (GenScript, Piscataway, NJ).
MYPT1(1-19) and (24-41) peptides were immobilized onto Sulfo-link beads (Pierce) via a
C-terminal Cys residue added for cross-linking, and then excess reactive groups on the beads
were quenched with 50 mM L-Cys.

Blank beads for controls were treated with 50 mM

L-Cys without peptide conjugation. H6S-P-T38-CPI-17 (0.1 µM) was mixed for 30 min at
23 °C, with 10 µL of slurry in 150 µL of 50 mM MOPS-NaOH, pH 7.0 including 0.1 M
NaCl, 1 mM EGTA, 0.1 % Tween 20, 5 % glycerol, 0.4 mM Pefabloc™, and 0.5 mM TCEP.
The beads were washed with 100 µL of the binding buffer 3 times, and bound CPI-17 was
detected by immunobloting with anti-CPI-17 using FluoroChemSP CCD imaging system
(Alpha-Innotech).

Relative amount of bound CPI-17 was obtained from three independent

experiments by quantifying the band intensity using AlphaEace FC imaging software.
17

Accession codes in Protein Data Bank and BioMagResBank
The atomic coordinates and the chemical shift table of P-T38-CPI-17(22-120)
protein are deposited in the Protein Data Bank (2RLT) and BioMagResoBank (15428),
respectively.
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FIGURE LEGENDS
Figure 1.

Inhibitory domain of CPI-17 family. (A) Amino acid sequence of CPI-17

family of PP1 inhibitor proteins.

Asterisk indicates Thr38, and arrows indicate Trp55, Ile77,

Leu80, and Leu81. Boxes show regions in helices A to D. (B) 1H-15N HSQC spectrum of
13

C/15N-labeled P-CPI-17 (1 mM).

Red, gray and blue indicate amide resonances of P-, U-,

and D38-CPI-17(22-120), respectively.

Resonance peaks of T38, V39 and V41 were

connected by arrows, from U-form to P- or D38-form.

Figure 2.

Solution NMR structure of phospho-CPI-17(22-120). (A) Stereo view

of the backbone of 20 superimposed structures obtained by NMR analysis. Red indicates the
region of α-helix. (B) Ribbon representation of an energy-minimized average structure. In
the ribbon model, the flexible N-terminal 31 residues are not depicted. T38 and residues
involved in hydrophobic clustering are drawn with ball-and-stick side chains labeled with
residue numbers to facilitate identification, and the helices are labeled with upper case letters.
(C) Space-filling representation with molecular surface potential, superimposed on backbone
structure (green).

Red and blue on surface indicate regions of negative and positive charges,

respectively. A side chain of P-T38 is drawn as ball-and-stick.

Figure 3.

Conformational transition of CPI-17 upon phosphorylation.

U-CPI-17 (1J2M) (left) D38-CPI-17 (1J2N) (middle) and P-T38-CPI-17 (right) are displayed
as ribbon structures.

Side chains of hydrophobic residues that tether Helix A to D are

shown as ball-and-stick for emphasis.

Figure 4.

Formation of the hydrophobic core in P-CPI-17.

(A) Top, middle, and

bottom panels represent the structures of U-, D38-, and P-T38-CPI-17, respectively.
Hydrophobic side chains responsible for the condensed conformation are displayed as Corey,
25

Pauling and Koltun colored model.

(B) Thermal stability of CPI-17 proteins monitored by

circular dichroism (CD). Vertical axis shows relative change of the molar ellipticity at 222
nm at indicated temperature. CD spectrum was measured with 20 µM protein; P-T38-CPI-17
(open circle), U-CPI-17 (closed circle), D38-CPI-17 (Rectangle), and P-T38-CPI-17 (Y41A)
(cross), in 50 mM potassium phosphate buffer, pH 7.0.

Mean values from triplicate assays

are shown.

Figure 5.

Effects of the mutation in the hydrophobic core on the inhibitory

potency of CPI-17. (A) Inhibition of myosin phosphatase purified from pig aorta. The
myosin phosphatase activity without inhibitor proteins was set as 100 %. Data are averaged
from two independent assays done in duplicate.

(B) Force measurement of vas deferens

smooth muscle strip. Panels represent the time-dependent force trace with U-CPI-17: wild
type, D73A/E74A, I77A/L80A/L81A and W55A.

The rabbit vas deferens smooth muscle

strips were permeabilized with beta-escin. The CPI-17 proteins were doped into the tissue
after the addition of PDBu.

The extent of contraction in the presence of 1 µM Ca2+ is set as

100 % value.

Figure 6.

Interaction of P-CPI-17 with PP1•MYPT1 complex.

(A) The

coordinates of MYPT1(1-299)•PP1 complex (1S70) in Protein Data Bank were used for
computer modeling of the complex. MYPT1 (yellow) and PP1 (cyan) are depicted in a
surface model, and P-T38-CPI-17 is drawn as a ribbon structure.

The positive charge of

MYPT1 Asp5 is shown as red, and the side chains of phospho-Thr38 and Arg43/44 in CPI-17
are shown as sticks.

(B) Binding assay of P-T38-CPI-17 was performed with synthetic

peptides corresponding to MYPT1 segments (1-19) and (24-41), immobilized on agarose
beads.

Asp5 is indicated by arrowhead in the sequence.

Bound P-T38-CPI-17 was

quantified by immunoblotting with anti-CPI-17 antibody (top).

Mean values from 3
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independent experiments are represented as a bar graph.

Student’s t test was used to assess

significance and * and ** indicate p > 0.15 and P < 0.03 respectively.
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